Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment

AIM: This phase I study investigated talazoparib pharmacokinetics (PK) and safety in patients with advanced solid tumours and varying degrees of hepatic function. METHODS: Patients with advanced solid tumours and normal hepatic function or varying degrees of hepatic impairment (mild, moderate or sev...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Cen, Yu, Yanke, Chakrabarti, Jayeta, Piha‐Paul, Sarina A., Moroose, Rebecca, Plotka, Anna, Shi, Haihong, Durairaj, Chandrasekar, Wang, Diane D., Wainberg, Zev A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314093/
https://www.ncbi.nlm.nih.gov/pubmed/35236002
http://dx.doi.org/10.1111/bcp.15294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314093/
https://www.ncbi.nlm.nih.gov/pubmed/35236002
http://dx.doi.org/10.1111/bcp.15294

Ejemplares similares